Esperion Therapeutics | ESPR - Interest Expense On Debt

Stock Price
2.78
Daily Change
0.16 5.92%
Monthly
-17.41%
Yearly
70.25%
Q1 Forecast
2.47

Esperion Therapeutics reported $22.64M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amarin USD 3K 5K Dec/2024
Amgen USD 653M 32M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Cipla INR 140.3M 8.5M Dec/2025
CSL USD 215M 111M Dec/2025
Cytokinetics USD 30.33M 4.01M Dec/2025
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
Geron USD 7.3M 1.35M Dec/2025
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Heron Therapeutics USD 600K 100K Dec/2024
Ionis Pharmaceuticals USD 18M 0 Dec/2025
Merck USD 412M 85M Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
Moderna USD 12.14B 12.13B Sep/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Sanofi EUR -25M 252M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
United Therapeutics USD 3.1M 100K Dec/2025
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025